Immunovant, Inc. (IMVT)
NASDAQ
Market Cap
$3.81B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
7 of 809
Rank in Industry
5 of 445
Largest Insider Buys in Sector
IMVT Stock Price History Chart
IMVT Stock Performance
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Insider Activity of Immunovant, Inc.
Over the last 12 months, insiders at Immunovant, Inc. have bought $58M and sold $15.47M worth of Immunovant, Inc. stock.
On average, over the past 5 years, insiders at Immunovant, Inc. have bought $28.03M and sold $6.62M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Roivant Sciences Ltd. () — $58M.
The last purchase of 1,526,316 shares for transaction amount of $58M was made by Roivant Sciences Ltd. () on 2023‑10‑02.
List of Insider Buy and Sell Transactions, Immunovant, Inc.
| 2024-05-22 | Sale | Salzmann Peter | Chief Executive Officer | 16,163 0.0112% | $29.65 | $479,233 | -10.94% | |
| 2024-05-22 | Sale | Butchko Julia G. | Chief Development Officer | 3,247 0.0022% | $29.65 | $96,274 | -10.94% | |
| 2024-05-22 | Sale | Macias William L. | Chief Medical Officer | 3,247 0.0022% | $29.65 | $96,274 | -10.94% | |
| 2024-05-22 | Sale | Barnett Eva Renee | Chief Financial Officer | 4,042 0.0028% | $29.65 | $119,845 | -10.94% | |
| 2024-05-22 | Sale | Levine Mark S. | Chief Legal Officer | 3,242 0.0022% | $29.65 | $96,125 | -10.94% | |
| 2024-04-24 | Sale | Levine Mark S. | Chief Legal Officer | 3,963 0.0028% | $28.90 | $114,531 | -4.10% | |
| 2024-04-24 | Sale | Stout Jay S | Chief Technology Officer | 7,239 0.005% | $28.90 | $209,207 | -4.10% | |
| 2024-04-24 | Sale | Geffner Michael | Chief Medical Officer | 3,261 0.0023% | $28.90 | $94,243 | -4.10% | |
| 2024-04-17 | Sale | Salzmann Peter | Chief Executive Officer | 34,079 0.024% | $29.06 | $990,269 | -0.32% | |
| 2024-04-17 | Sale | Butchko Julia G. | Chief Development Officer | 10,115 0.0071% | $29.06 | $293,923 | -0.32% | |
| 2024-04-17 | Sale | Macias William L. | Chief Medical Officer | 8,280 0.0058% | $29.06 | $240,602 | -0.32% | |
| 2024-04-17 | Sale | Barnett Eva Renee | Chief Financial Officer | 12,253 0.0086% | $29.06 | $356,049 | -0.32% | |
| 2024-04-17 | Sale | Levine Mark S. | Chief Legal Officer | 9,827 0.0069% | $29.06 | $285,554 | -0.32% | |
| 2024-04-09 | Sale | Salzmann Peter | Chief Executive Officer | 4,807 0.0033% | $31.18 | $149,882 | -8.79% | |
| 2024-04-09 | Sale | Butchko Julia G. | Chief Development Officer | 1,053 0.0007% | $31.18 | $32,833 | -8.79% | |
| 2024-04-09 | Sale | Barnett Eva Renee | Chief Financial Officer | 3,689 0.0025% | $31.18 | $115,023 | -8.79% | |
| 2024-02-22 | Sale | Salzmann Peter | Chief Executive Officer | 13,454 0.0093% | $36.15 | $486,362 | -16.98% | |
| 2024-02-22 | Sale | Butchko Julia G. | Chief Development Officer | 2,146 0.0015% | $36.15 | $77,578 | -16.98% | |
| 2024-02-22 | Sale | Macias William L. | Chief Medical Officer | 2,221 0.0015% | $36.15 | $80,289 | -16.98% | |
| 2024-02-22 | Sale | Barnett Eva Renee | Chief Financial Officer | 2,930 0.002% | $36.15 | $105,920 | -16.98% |
Insider Historical Profitability
88.18%
| Roivant Sciences Ltd. | 79805331 55.1668% | $26.06 | 5 | 0 | +39.82% | |
| Salzmann Peter | Chief Executive Officer | 1036716 0.653% | $26.06 | 0 | 21 | |
| Butchko Julia G. | Chief Development Officer | 448380 0.2834% | $26.06 | 1 | 19 | <0.0001% |
| Macias William L. | Chief Medical Officer | 374403 0.2303% | $26.06 | 0 | 15 | |
| Barnett Eva Renee | Chief Financial Officer | 355414 0.2235% | $26.06 | 0 | 13 | |
| Levine Mark S. | Chief Legal Officer | 339914 0.2102% | $26.06 | 0 | 11 | |
| Stout Jay S | Chief Technology Officer | 147739 0.1017% | $26.06 | 0 | 1 | |
| MIGAUSKY GEORGE V | director | 109808 0.0759% | $26.06 | 1 | 1 | <0.0001% |
| Geffner Michael | Chief Medical Officer | 141616 0.0621% | $26.06 | 0 | 2 | |
| Fromkin Andrew J. | director | 88658 0.0613% | $26.06 | 1 | 1 | <0.0001% |
| Pande Atul | director | 83158 0.0575% | $26.06 | 2 | 1 | +99.07% |
| WONG RODERICK | Chief Executive Officer | 902498 0.6239% | $26.06 | 22 | 0 | +118.39% |
| Hughes Douglas J. | director | 58447 0.0404% | $26.06 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Fidelity Investments | $247.36M | 5.24 | 7.66M | -2.79% | -$7.1M | 0.02 | |
| The Vanguard Group | $209.31M | 4.44 | 6.48M | +11.16% | +$21.02M | <0.01 | |
| BlackRock | $144.65M | 3.07 | 4.48M | -1.19% | -$1.74M | <0.01 | |
| State Street | $117.67M | 2.49 | 3.64M | +13.23% | +$13.75M | 0.01 | |
| Perceptive Advisors | $95.74M | 2.03 | 2.96M | +27.28% | +$20.52M | 0.06 | |
| Armistice Capital Llc | $69.92M | 1.48 | 2.16M | +50.7% | +$23.52M | 0.84 | |
| Alpine Global Management, LLC | $60.83M | 1.29 | 1.88M | +34.63% | +$15.65M | 3.93 | |
| T. Rowe Price | $60.16M | 1.28 | 1.86M | +16.19% | +$8.38M | 0.01 | |
| Viking Global Investors | $58.45M | 1.24 | 1.81M | New | +$58.45M | 0.02 | |
| Logos Global Management Lp | $57.35M | 1.22 | 1.77M | +47.92% | +$18.58M | 6.16 | |
| Point72 Asset Management | $44.71M | 0.95 | 1.38M | -48.11% | -$41.46M | 0.09 | |
| Geode Capital Management | $42.55M | 0.9 | 1.32M | +3.45% | +$1.42M | <0.01 | |
| Woodline Partners LP | $41.66M | 0.88 | 1.29M | +71.87% | +$17.42M | 0.39 | |
| Alger | $41.09M | 0.87 | 1.27M | +43.72% | +$12.5M | 0.2 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $37.16M | 0.79 | 1.15M | +16.97% | +$5.39M | 0.95 | |
| Nuveen | $35.68M | 0.76 | 1.1M | -10.02% | -$3.97M | 0.01 | |
| Capital Research Global Investors | $31.54M | 0.67 | 976,237 | 0% | +$0 | 0.01 | |
| Redmile Group | $31.33M | 0.66 | 969,621 | -0.76% | -$240,741.81 | 1.16 | |
| Morgan Stanley | $30.31M | 0.64 | 937,961 | +76.47% | +$13.13M | <0.01 | |
| Franklin Templeton Investments | $28.08M | 0.6 | 869,216 | +61.24% | +$10.67M | 0.01 | |
| Boxer Capital, LLC | $26.66M | 0.57 | 825,000 | -17.5% | -$5.65M | 1.33 | |
| Paradigm BioCapital Advisors LP | $25.82M | 0.55 | 799,054 | New | +$25.82M | 0.94 | |
| Commodore Capital, LP | $24.26M | 0.51 | 750,990 | -24.9% | -$8.05M | 1.71 | |
| Lord Abbett | $20.35M | 0.43 | 629,882 | -0.24% | -$49,013.10 | 0.07 | |
| Dimensional Fund Advisors | $18.53M | 0.39 | 573,447 | -19.45% | -$4.48M | 0.01 | |
| Kairos Capital Management Lp | $17.49M | 0.37 | 541,295 | +172.35% | +$11.07M | 8.37 | |
| Invesco | $17M | 0.36 | 526,233 | +6.93% | +$1.1M | <0.01 | |
| Avidity Partners Management Lp | $16.32M | 0.35 | 505,000 | +106.12% | +$8.4M | 0.59 | |
| Deep Track Capital Lp | $15.94M | 0.34 | 493,352 | -50.66% | -$16.37M | 0.07 | |
| Northern Trust | $15.47M | 0.33 | 478,707 | -3.23% | -$516,540.00 | <0.01 | |
| PFM Health Sciences | $15.27M | 0.32 | 472,540 | 0% | +$0 | 0.42 | |
| Millennium Management LLC | $14.83M | 0.31 | 459,027 | -31.63% | -$6.86M | 0.01 | |
| Charles Schwab | $14.28M | 0.3 | 442,084 | +1.15% | +$161,679.24 | <0.01 | |
| Baker Bros Advisors LP | $13.73M | 0.29 | 425,009 | 0% | +$0 | 0.17 | |
| Wellington Management Company | $13.17M | 0.28 | 407,654 | +38.18% | +$3.64M | <0.01 | |
| Goldman Sachs | $11.28M | 0.24 | 349,177 | -23.78% | -$3.52M | <0.01 | |
| Renaissance Technologies | $10.98M | 0.23 | 339,700 | +1,756.28% | +$10.38M | 0.02 | |
| Victory Capital Management Inc | $10.31M | 0.22 | 319,001 | -2.01% | -$211,081.24 | 0.01 | |
| Emerald Advisers, Inc. | $9.78M | 0.21 | 302,789 | -1.14% | -$112,309.57 | 0.4 | |
| Rafferty Asset Management Llc | $9.35M | 0.2 | 289,385 | +26.32% | +$1.95M | 0.03 | |
| Affinity Asset Advisors | $9.21M | 0.2 | 285,000 | -17.39% | -$1.94M | 1.64 | |
| SEB | $8.93M | 0.19 | 277,022 | -59.38% | -$13.05M | 0.04 | |
| Ikarian Capital LLC | $8.95M | 0.19 | 276,925 | +18.65% | +$1.41M | 2.55 | |
| Octagon Capital Advisors LP | $8.83M | 0.19 | 273,289 | 0% | +$0 | 1.16 | |
| Soleus Capital Management, L.P. | $8.55M | 0.18 | 264,650 | -16.53% | -$1.69M | 0.08 | |
| Eversept Partners LP | $8.26M | 0.18 | 255,526 | +124.55% | +$4.58M | 0.62 | |
| Citigroup | $8.07M | 0.17 | 249,791 | +100.89% | +$4.05M | 0.01 | |
| Senator Investment Group LP | $8.08M | 0.17 | 250,000 | +42.86% | +$2.42M | 0.37 | |
| JPMorgan Chase | $7.92M | 0.17 | 245,033 | -47.98% | -$7.3M | <0.01 | |
| Susquehanna International Group | $7.87M | 0.17 | 243,643 | +22.61% | +$1.45M | 0.01 |